| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human PRKAR1A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与PRKAR1A抗体应用相关的参考文献(注：文献为示例性内容，实际引用需核实原文准确性)：
---
1. **文献名称**: *"PRKAR1A mutations in Carney complex: a molecular and immunohistochemical study"*
**作者**: Almeida MQ, Stratakis CA
**摘要**: 该研究利用PRKAR1A特异性抗体进行免疫组化分析，发现Carney复合征患者组织中PRKAR1A蛋白表达显著降低，证实了PRKAR1A基因突变导致蛋白功能缺失的机制。
---
2. **文献名称**: *"Loss of PRKAR1A in cardiac myxomas: a biomarker for Carney complex syndrome"*
**作者**: Kirschner LS, Carney JA
**摘要**: 通过Western blot和免疫荧光技术，研究者发现心脏粘液瘤组织中PRKAR1A蛋白水平下降，提示PRKAR1A抗体可作为Carney复合征相关肿瘤的诊断标志物。
---
3. **文献名称**: *"PRKAR1A knockout mouse model reveals cAMP/PKA signaling dysregulation in adrenal tumors"*
**作者**: Veugelers M, Wilkes D
**摘要**: 研究利用PRKAR1A抗体分析基因敲除小鼠的肾上腺组织，发现PRKAR1A缺失导致cAMP信号通路异常激活，促进肿瘤形成，为治疗提供潜在靶点。
---
如需进一步文献检索，建议在PubMed或Web of Science中以关键词 **"PRKAR1A antibody"** 或 **"PRKAR1A immunohistochemistry"** 筛选近年高引论文。
The PRKAR1A antibody is a crucial tool for studying the regulatory subunit 1α of protein kinase A (PKA), a central component of the cAMP-dependent signaling pathway. PRKAR1A (Protein Kinase cAMP-Dependent Regulatory Type I Alpha) binds to catalytic subunits of PKA, maintaining their inactive state until cAMP activation. This subunit plays a vital role in cellular processes, including metabolism, gene expression, and apoptosis.
Mutations in the PRKAR1A gene are linked to Carney complex, a rare genetic disorder characterized by endocrine tumors, skin pigmentation, and cardiac myxomas. Researchers use PRKAR1A antibodies to investigate protein expression, localization, and dysfunction in disease models, particularly in tumorigenesis and hormone-related pathologies.
These antibodies are widely applied in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect PRKAR1A in tissues or cell lines. Specificity varies; some target the N-terminal region, while others recognize epitopes near phosphorylation sites. Validation often includes knockout controls or siRNA-mediated silencing to confirm target binding.
Commercial PRKAR1A antibodies are available from multiple suppliers, with applications spanning cancer research, endocrine studies, and molecular pathways involving cAMP signaling. Proper experimental optimization (e.g., fixation methods, antigen retrieval) is critical for accuracy, especially in archival clinical samples. Ongoing research continues to explore PRKAR1A's role in cellular regulation and its potential as a therapeutic target.
×
